IND-enabling safety tox studies for FDA submission in just 9 months

Learn how Syngene supported a pharma company in completing IND-enabling safety tox studies for their lead compound for treating painful neuropathies in less than nine months.

Author

Latest Blogs

Antibody drug conjugate delivering a cytotoxic payload to a cancer cell via a chemical linker

The rise of ADCs in oncology: how antibody drug conjugate therapies deliver precision

Scientists reviewing records on a tablet, process knowledge management

Tech transfer in CDMOs: avoiding the scale-up trap

Self-amplifying RNA vaccine vials and syringe representing mRNA-based therapeutics

Self-amplifying RNA: the next chapter in mRNA therapeutics

Laboratory glassware with green leaves illustrating green chemistry in pharmaceuticals.

Green chemistry principles for a sustainable future in pharma

Integrated drug discovery scientist analysing digital lab data

Integrated Drug Discovery: why expertise matters

Bispecific antibodies: engineering complexity into simplicity

To view or email, Please share your details view

Your browser does not support this function.

To download, Please share your details

To view or email, Please share your details view

To download, Please share your details